Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

National Institutes of Health
Award USD 0–1M ≈ €0–€920K
Closing date 726 days left · May 07, 2028
Location Global
For Orgs

About this opportunity

This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of Alzheimer's Disease and related dementias. The program seeks to advance translational bioinformatics and experimental approaches to identify promising therapeutic candidates through preclinical validation.

Who can apply

Applicant Types

organization

Organization Types

nonprofit, academic, for profit, government, tribal

Project Locations

🇺🇸 United States

Region

United States

How to apply

Stages

  1. 1 single_stage

Required documents

research_proposal · budget

Restrictions

  • no_concurrent_funding

Post-award obligations

  • final_report
  • acknowledge_funder